Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.72 |
| ▸ | HTR2C | P28335 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195032 | 0.85 | HTR2C (0.57) | PIK3CAHTR2CKDM4EMEN1MAPT | |
| SCHEMBL13944181 | 0.84 | HTR2C (0.79) | PIK3CAHTR2CBCDIN3D | |
| SCHEMBL2190223 | 0.82 | GAA (0.65) | PIK3CAGAAKDM4EMEN1CYP1A2 | |
| SCHEMBL13944737 | 0.82 | BCDIN3D (0.71) | PIK3CAHTR2CMEN1KMT2ABCDIN3D | |
| SCHEMBL2189865 | 0.81 | PIK3CA (0.82) | PIK3CAHTR2CBCDIN3D | |
| SCHEMBL13946808 | 0.81 | PIK3CA (0.66) | PIK3CAHTR2CKDM4EMEN1CYP1A2 | |
| SCHEMBL3757124 | 0.81 | HTR2C (1.00) | PIK3CAHTR2C | |
| SCHEMBL2190241 | 0.81 | PIK3CA (1.00) | PIK3CAHTR2CBCDIN3D | |
| SCHEMBL13944361 | 0.81 | PIK3CA (1.00) | PIK3CAHTR2C | |
| SCHEMBL3757023 | 0.81 | HTR2C (1.00) | PIK3CAHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2252616-B1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2252616-B1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| EP-2252616-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009097446-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097446-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | PIK3CA 1/4885HTR2C 4039/4885GAA 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.